Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

1.

Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study.

Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J.

J Clin Psychopharmacol. 2008 Apr;28(2):210-3. doi: 10.1097/JCP.0b013e318167269d. Erratum in: J Clin Psychopharmacol. 2008 Dec;28(6):624.

PMID:
18344732
2.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
3.
4.

Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.

Parellada E, Andrezina R, Milanova V, Glue P, Masiak M, Turner MS, Medori R, Gaebel W.

J Psychopharmacol. 2005 Sep;19(5 Suppl):5-14.

PMID:
16144781
5.

[Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].

Raignoux C, Dusouchet T, Bret P, Queuille E, Biscay ML, Caron J, Bret MC.

Encephale. 2007 Dec;33(6):973-81. doi: 10.1016/j.encep.2006.07.003. Epub 2007 Sep 4. French.

PMID:
18789790
6.

Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.

Hawley C, Turner M, Latif MA, Curtis V, Saleem PT, Wilton K.

Hum Psychopharmacol. 2010 Jan;25(1):37-46. doi: 10.1002/hup.1085.

PMID:
20041474
7.

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.

Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O.

J Clin Psychiatry. 2003 Oct;64(10):1250-7.

PMID:
14658976
8.

Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.

Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A.

Eur Psychiatry. 2010 May;25(4):220-9. doi: 10.1016/j.eurpsy.2009.09.001. Epub 2009 Nov 18.

PMID:
19926263
9.

Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.

Barrio P, Batalla A, Castellví P, Hidalgo D, García M, Ortiz A, Grande I, Pons A, Parellada E.

Int Clin Psychopharmacol. 2013 Jul;28(4):164-70. doi: 10.1097/YIC.0b013e3283611cc3.

PMID:
23587986
10.

Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.

Rossi A, Bagalà A, Del Curatolo V, Scapati F, Bernareggi MM, Giustra MG; Risperidone Long-Acting Trial Investigators (R-LAI).

Hum Psychopharmacol. 2009 Oct;24(7):574-83. doi: 10.1002/hup.1067.

PMID:
19790173
11.

Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies.

Möller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E; StoRMi Study Group.

Int Clin Psychopharmacol. 2005 May;20(3):121-30.

PMID:
15812261
12.

Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.

Arunpongpaisal S, Srisurapanont M, Kongsakon R, Kitiwattanagul K, Samanwongthai U.

J Med Assoc Thai. 2010 Mar;93(3):343-50.

PMID:
20420110
13.

Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients.

Kissling W, Glue P, Medori R, Simpson S.

Hum Psychopharmacol. 2007 Dec;22(8):505-13.

PMID:
17902187
14.

A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.

Lee NY, Kim SH, Cho SJ, Chung YC, Jung IK, Kim CY, Kim DH, Lee DG, Lee YH, Lim WJ, Na YS, Shin SE, Woo JM, Yoon JS, Yoon BH, Ahn YM, Kim YS.

Int Clin Psychopharmacol. 2014 Sep;29(5):279-87. doi: 10.1097/YIC.0000000000000030.

PMID:
24583566
15.

Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders.

Lai YC, Huang MC, Chen CH, Tsai CJ, Pan CH, Chiu CC.

Psychiatry Clin Neurosci. 2009 Aug;63(4):440-8. doi: 10.1111/j.1440-1819.2009.01977.x. Epub 2009 Apr 27.

16.

A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.

Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, Rodriguez S, Gharabawi GM.

J Clin Psychiatry. 2006 Aug;67(8):1194-203.

PMID:
16965196
17.

Long-acting risperidone in stable patients with schizoaffective disorder.

Mohl A, Westlye K, Opjordsmoen S, Lex A, Schreiner A, Benoit M, Bräunig P, Medori R.

J Psychopharmacol. 2005 Sep;19(5 Suppl):22-31.

PMID:
16144783
18.

Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Int Clin Psychopharmacol. 2008 Nov;23(6):325-31. doi: 10.1097/YIC.0b013e32830c2042.

PMID:
18854720
19.

A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.

Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM.

J Clin Psychiatry. 2009 Oct;70(10):1397-406. doi: 10.4088/JCP.09m05284yel.

PMID:
19906343
20.

Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.

Lasser RA, Bossie CA, Zhu Y, Gharabawi G, Eerdekens M, Davidson M.

Int J Geriatr Psychiatry. 2004 Sep;19(9):898-905.

PMID:
15352149

Supplemental Content

Support Center